American Specialty Lab LLC

American Specialty Lab LLC was paid $497K by Medicaid between Jan 2018 and Dec 2024, across 57 billing codes. Its largest line is G0480, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed — 33% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Nevada

Rank by total paid#14 of 31

Median peer was paid$269K

This provider vs. median1.9×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	11,350	$105K
2019	4,332	$60K
2020	7,700	$64K
2021	9,805	$65K
2022	10,652	$138K
2023	5,058	$36K
2024incomplete	4,631	$30K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	33%	6,747	6,200	$165K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	31%	8,504	7,818	$153K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	20%	2,383	1,580	$101K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	6.9%	793	746	$34K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	1.8%	1,936	1,326	$9K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	1.2%	2,127	1,569	$6K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.0%	1,522	1,258	$5K
80061	Lipid panel	<1%	3,163	2,651	$5K
80050	General health panel	<1%	201	183	$4K
83036	Hemoglobin; glycosylated (A1C)	<1%	2,560	2,135	$3K
80053	Comprehensive metabolic panel	<1%	4,011	3,334	$2K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	3,361	2,761	$2K

45 more codes

84443	Thyroid stimulating hormone (TSH)	<1%	2,626	$1K
82607		<1%	686	$1K
36415	Collection of venous blood by venipuncture	<1%	4,022	$953.51
84439		<1%	498	$595.11
87086	Culture, bacterial; quantitative colony count, urine	<1%	233	$270.33
86769		<1%	18	$210.66
82670		<1%	13	$209.66
84403		<1%	16	$193.71
G0306	Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count	<1%	543	$193.12
81001		<1%	469	$192.37
84402		<1%	14	$191.07
84550		<1%	595	$166.32
84270		<1%	14	$163.13
84481		<1%	143	$161.84
84311		<1%	428	$157.41
84144		<1%	14	$156.53
84146		<1%	15	$145.42
83001		<1%	13	$126.80
83002		<1%	13	$126.30
82570		<1%	435	$123.55
82533		<1%	13	$122.32
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	15	$119.70
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	15	$119.70
84153		<1%	202	$112.95
84436		<1%	142	$112.56
82728		<1%	47	$111.60
82746		<1%	33	$100.30
84480		<1%	15	$87.03
83540		<1%	66	$62.24
83021		<1%	71	$61.60
83735		<1%	35	$50.27
86140		<1%	17	$35.30
84100		<1%	15	$32.30
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	4,040	$30.93
87077		<1%	17	$22.08
83986		<1%	426	$21.96
81003		<1%	57	$12.24
84479		<1%	17	$8.84
84466		<1%	28	$8.71
82043		0%	13	$0.00
85652		0%	52	$0.00
84154		0%	13	$0.00
G0103	Prostate cancer screening; prostate specific antigen test (psa)	0%	15	$0.00
80048	Basic metabolic panel (calcium, ionized)	0%	16	$0.00
99001		0%	32	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialPRESCOTT, NICK (CEO)

Same official

Other billing entities under PRESCOTT, NICK

Full network →

Provider	Location	Paid
Laboratory Services, LLC	Costa Mesa, CA	$3K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.